DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Loss of PEDF: A Novel Mechanism of Antihormone Resistance in Breast Cancer
Technical Report,01 Aug 2012,31 Jul 2015
University of Kansas Medical Center Kansas City United States
Pagination or Media Count:
Resistance to endocrine therapy such as tamoxifen or aromatase inhibitors is a major clinical obstacle to the effective treatment and cure of women with estrogen receptor ER-positive breast cancer. It is estimated that 40 of breast cancer patients will develop endocrine-resistant disease following long-term treatment. The possibility of identifying new targets for therapy in resistant disease, or patients, who may benefit from additional treatment with existing therapies, provides a strong impetus to identify markers and mediators of therapeutic resistance. Our laboratory has identified a novel protein called pigment epithelium derived factor PEDF that appears to be suppressedsilenced in endocrine resistant breast cancer.
APPROVED FOR PUBLIC RELEASE